JPH03297364A - Powdery composition for preventing thrombosis - Google Patents

Abstract

PURPOSE:To obtain the subject composition, containing fats and oils containing eicosapentaenoic acid, etc., lecithin and proteins, etc., in a specific proportion, excellent in preservation stability and effective against artericsclerotic, thrombot ic and cerebral angiopathic diseases. CONSTITUTION:The objective composition containing (A) 20-70wt.% fats and oils containing >=10wt.% eicosapentaenoic acid and docosapentaenoic-acid and/or >=20wt.% alpha-linolenic acid, (B) 2-20wt.% lecithin and (C) 20-70wt.% proteins and/or hydrolyzates thereof.

Description

Detailed Description of the Invention [Industrial Field of Application] The present invention provides a novel powder composition for preventing blood clots, more specifically, for use in patients with a history of cerebral infarction, myocardial infarction, or angina pectoris, or with a tendency to arteriosclerosis. The present invention relates to a powder composition for preventing blood clots that has excellent long-term storage stability and is useful for people with high blood triglyceride and cholesterol levels.

[Prior Art] In recent years, in Japan, with the rapid aging of the population, the number of adult diseases, particularly hypertension, myocardial infarction, arteriosclerosis,
Thrombosis is rapidly increasing and has become a major problem.

In the 1970s, an epidemiological study of the Niskimo people in Greenland found that areas with high fish intake had fewer adult cases of arteriosclerotic disease.
y) J Vol. 15, pp. 117-119 (1987)], the importance of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as having preventive effects against the above-mentioned diseases has been recognized. It has been attracting attention.

However, eicosabencitric acid and docosahexaenoic acid are highly unsaturated fatty acids that are easily oxidized, have a strong unpleasant odor, and have problems such as not being able to be eaten in large quantities as food. Therefore, fats and oils containing these are coated with soft gelatin capsules and marketed as foods.

On the other hand, recently, a powder product obtained by spray drying (Japanese Patent Laid-Open No. 60-49
No. 097, JP-A No. 62-126933) have been studied, and oil-in-water emulsions of purified fish oil etc. and aqueous solutions of water-utilizing proteins (JP-A No. 60-102) have been studied.
No. 168) is also being considered. On the other hand, oils and fats containing lecithin and eicosapentaenoic acid and docosahexaenoic acid (Japanese Unexamined Patent Publication No. 1982-12020) have been studied as compositions having high antithrombotic and antiarteriosclerotic activity.

By the way, eicosapentaenoic acid and docosahexaenoic acid are the starting fatty acids of the prostaglandin E system, and are also recognized to prevent hypertension and cerebral thrombosis due to their antagonistic effects on arachidonic acid metabolism.

In general, highly unsaturated acids, particularly eicosapencitric acid and docosahexaenoic acid, are susceptible to deterioration due to heat and wrinkles, tend to produce off-odor and yellow color, and have the disadvantage of extremely poor storage stability. Furthermore, peroxides produced by oxidation of these fatty acids are known to be toxic to the human body.

Capsules of fish oil, eicosapentaenoic acid, and docosahexaenoic acid concentrate currently on the market are difficult to dissolve in water and use, and also cause eructation after drinking. In addition, powder products obtained by spray drying that are currently commercially available have a strong unpleasant odor and bad aftertaste when dissolved in water and are difficult to drink continuously. Even when used in food, the characteristic fishy odor of fish oil spreads throughout the mouth, making it inevitable to lose the desire to eat.

In particular, powdered oil products containing eicosapencitric acid or docosahexaenoic acid have a strong fish oil odor and become difficult to eat if more than two months have passed since they were manufactured.

Furthermore, the use of oils and fats containing eicosapencitric acid and docosahexaenoic acid is being considered;
It cannot be said that it is sufficiently effective in improving conditions such as arteriosclerosis.

Furthermore, at present, no product has been found that can prevent these symptoms, improve pathological conditions, and provide sufficient nutrition.

[Problems to be Solved by the Invention] Under these circumstances, the present invention has a simple usage form, excellent storage stability, and is effective for improving the condition of patients with cerebrovascular disorders, arteriosclerosis, and thrombosis. The purpose of this invention is to provide a composition that is effective in preventing and treating diseases and the like, as well as providing sufficient nutritional support and improving effects.

[Means for Solving the Problems] As a result of intensive research by the present inventors to develop a composition having the above-mentioned preferable properties, the present inventors have found that oils and fats containing predetermined amounts of eicosapentaenoic acid and docosahexaenoic acid and 0/or α - an oil or fat containing a predetermined amount of linolenic acid, and lecithin;
The inventors discovered that the object could be achieved by using a powder composition containing protein and/or its decomposition products in specific proportions, and based on this knowledge, the present invention was completed.

That is, the present invention provides (A) an oil or fat containing 10% by weight or more of eicosapentaenoic acid and docosahexaenoic acid and/or 20% by weight of a-linolenic acid. ! ! % or more, (B) 22-20% by weight of wrench, and (C) 20-70% by weight of protein and/or decomposed products thereof. A composition is provided.

The present invention will be explained in detail below.

In the composition of the present invention, as component (A), an oil or fat containing 10% by weight or more of eicosapentaenoic acid and docosahexaenoic acid, an oil or fat containing 20% by weight or more of α-linolenic acid, or a mixture of these oils and fats is used.

The eicosapentaenoic acid and docosahexaenoic acid 10
Examples of fats and oils containing % by weight or more include edible fish oil,
That is, purified or concentrated fish oils such as sardine oil, mackerel oil, herring oil, and cod liver oil can be used, and also those extracted from bacteria, chlorella, etc. can be used.

On the other hand, as the oil containing 20% by weight or more of α-linolenic acid, for example, perilla oil or perilla oil, which is an oil obtained from the labiataceous plant of the mint family, is used. This σ-linolenic acid is an omega-3 highly unsaturated fatty acid like the above-mentioned eicosapencitric acid and docosahexaenoic acid, and is known to have a preventive effect against hypertension, cerebral infarction, myocardial infarction, etc.

In the composition of the present invention, lecithin used as component (B) chemically means phosphatidylcholine, but in the present invention it refers to a mixture with phospholipids such as phos-7 atidylethanolamine and phosphatidylinositol. This lecithin can be prepared by extracting it from seeds such as soybeans and sunflowers, eggs, various bacteria, etc., or it can also be prepared by synthesis, but due to cost considerations, commercially available soybean phospholipids and egg yolks can be used. Preference is given to using phospholipids. It is also possible to use water-soluble lecithin obtained by defatting and enzymatically treating lecithin. In the present invention, those containing a large amount of phosphatidylcholine are preferable because they can better prevent the generation of deterioration odor.

In the composition of the present invention, the protein and/or its decomposition product used as component (C) has high nutritional value as a protein, has a coating effect on fats and oils, and has an antioxidant effect and a cholesterol-lowering effect on fats and oils. Things can be mentioned. These include, for example, egg protein, whey (whey and lactalbumin) protein, soy protein, fish protein, casein,
Examples include gelatin and decomposition products thereof. These may be used alone or in combination of two or more.

These proteins are important involved in cholesterol metabolism and are thought to have the effect of promoting the prevention and ameliorating effects of eicosapentaenoic acid and docosahexaenoic acid on arteriosclerosis and thrombosis. In addition, protein is an important nutrient that is a constituent of the body, and is effective in increasing physical strength and preventing complications from complications.

In the composition of the present invention, component (A) is eicosapentaenoic acid and docosahexaene lt! 20-70% by weight of fats and oils containing 10% by weight or more and/or 20% by weight or more of σ-linolenic acid, 2-20% by weight of lecithin as component (B), and protein and fats as component (C). /
Alternatively, it is necessary to contain a decomposed product thereof in a proportion of 20 to 70% by weight. If the ratio of each component deviates from the above range, the effects of the present invention will not be fully exhibited. The composition of the present invention may contain carbohydrates such as dextrin, lactose, sucrose, and glucose, as well as micronutrients such as vitamins and minerals, as well as antioxidants and emulsifiers. , emulsion stabilizers, fruit juices, fragrances, etc. can be added.

The emulsifier is used to make the oil particles finer and sufficiently covered with water-soluble components in the preparation of the emulsion before powdering, and also to improve the resulting powder granule composition. It is appropriately blended to maintain good emulsion stability after dissolving the substance. As the emulsifier, for example, sucrose fatty acid ester, fatty acid monoglyceride, propylene glycol fatty acid ester, sorbitan fatty acid ester, etc. can be used, but in particular organic acid monoglycerides such as succinic acid monoglyceride, citric acid monoglyceride, and tetraglycerol pentaoleate. Polyglycerol fatty acid esters are preferred.

Next, to explain one example of a suitable manufacturing method of the powder composition for thrombosis prevention of the present invention, lecithin and optionally used antioxidants, emulsifiers, fragrances, etc. are added to oil and fat, and then dissolved by heating. to prepare the oil phase. Separately, proteins and/or their decomposition products, carbohydrates, minerals, emulsion stabilizers, fruit juices, fragrances, etc., are added to water in an amount of 2 to 5 times the total solid content. and completely dissolve while stirring at a temperature of about 40 to 80°C to prepare an aqueous phase. Next, the aqueous phase and the oil phase are mixed with stirring to prepare a preliminary emulsion, and then spray-dried to produce a powder composition. If necessary, add protein, carbohydrates, vitamins,
Minerals and the like may be mixed in powder form and then granulated using an appropriate granulation method. As the granulation method, for example, a fluidized bed granulation method can be used.

The powder composition thus obtained has good storage stability. This is because the surface of the oil particles containing eicosapentaenoic acid and docosahexaenoic acid is coated with lecithin, and the outside is further coated with protein, which sufficiently protects the oil containing eicosapentaenoic acid and docosahexaenoic acid. , it is thought that the storage stability will be good. In particular, it is thought that the coating effect of lecithin is significant.

The powder composition of the present invention has excellent storage stability and contains high-quality protein, which is an important nutrient, so it has the ability to prevent and improve thrombosis through effects such as increasing physical strength. .

In order to store this blood clot prevention powder composition stably for a long time! It is desirable to seal 5 to 100 g each using a packaging container with almost no oxygen permeability and/or an oxygen absorber.

The composition of the present invention may be dissolved in water or hot water and taken as a drink, or may be added to concentrated liquid food and administered orally or enterally. It can also be used as an ingredient in processed foods.

[5! Examples] Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited to these Examples in any way.

Example 1 100 parts of the material having the composition shown in Table 1 was added to 200 parts by weight of water.
Add parts by weight and raise the temperature to 70°C. Soybean lecithin and succinic acid monoglyceride are pre-mixed with eicosapentaenoic acid (E
Concentrated fish oil (EPA: 17 Wi%, DHA: 12 wt%) containing PA) and docosahexaenoic acid (DHA)
) and perilla oil (σ-linolenic @: 56 wt%)
After dissolving it in the blended oil, it was added. In addition, oil has
Natural vitamin mix (d-σ-tocopherol 50w
(t% content) was added at a ratio of 0.05 wt% to oil.

After pre-emulsifying this mixture at 70°C for 15 minutes,
Tier 200 kg/cm2.2nd tier 50 kg/cm”
A two-stage homogenization method was used to obtain an emulsion, and the emulsion was then dried using a spray dryer to obtain a powder product.

The powder product thus obtained is placed in a fluidized bed granulator and granulated while spraying purified water into the fluidized bed. Seal 159 pieces of this granule product in aluminum foil film pouches while sealing with nitrogen gas. Granule product in this sachet 159
I dissolved it in 150+1 liters of warm water and drank it, and it had no irritating or off-taste and was delicious to drink.

In addition, the granule product in the sachet after being stored at room temperature for 6 months has no change in color, odor, or properties compared to the product immediately after manufacture, and the peroxide value (POV) of the oil content of the granule product is 5.0 meq/kg.
It's low, so there's no problem. It was also possible to dissolve it in warm water and drink it deliciously.

Furthermore, the granule product in this sachet was dissolved in a commercially available concentrated liquid diet (San-Etto-A) and administered via tube. When this solution was left at room temperature for 8 hours and at 5°C for 2 days, no oil separated and the emulsion stability was good. Moreover, when these were left as they were, there was no increase in POv.

(Margin below) Table 1 Comparative Example 1 A granule product was obtained in the same manner as in Example 1, except that lecithin was omitted from the ingredients listed in Table 1, and sealed in a sachet. After storing this at room temperature for 6 months, the odor and other characteristics were evaluated, and the oil had a strong odor of rancidity, and could not be used as a product.

Example 2 Add 100 parts by weight of the material having the composition shown in Table 2 to 200 parts by weight of water.
parts by weight were added, and the temperature was raised to 70°C. Egg yolk lecithin and tetraglycerin pentaoleate are prepared using purified fish oil (E
PA: 10wt%, DHA: 8wt%) and perilla demonstration (
A-linolenic acid (63 wt%) was dissolved in a blended oil and then added.

In addition, natural vitamin mix is added to the oil at 0.05wt% to oil.
It was added at a ratio of After pre-emulsifying this mixture at 75°C for 15 minutes, the first stage was 200ky/cm2.
kg/cm" to obtain an emulsion using a two-step homogenization method. This emulsion was then dried in a spray dryer to obtain a powder product. 1 kg each of this powder product was placed in an aluminum foil film bag. , and an oxygen scavenger (Ageless Z-20, manufactured by Mitsubishi Gas Chemical Co., Ltd.) and stored at room temperature for 6 months.
It was in good condition with no odor of deterioration. When this product was used as part of an ingredient in puddings, margarines, spreads, sausages, and ice creams, the products had a good flavor without the unpleasant odor of fish oil.

(Margins below) Table Example 3 Add 100 parts by weight of the ingredients listed in Table 3 excluding lactalbumin and skim milk powder to 200 parts by weight, and heat to 70°C.
The temperature rose to . Citric acid monoglyceride is pre-treated with EPA,
DHA concentrated fish oil (EPA: 25wt%, DHA: 14w
t%) and perilla oil (aliluric acid: 58 wt%) and then added. A natural vitamin mix was added to the oil at a ratio of 0.05 wt% to the oil. After pre-emulsifying this mixture at 75°C for 15 minutes,
The emulsion was homogenized using a two-step homogenization method at 50 kg/cm'' and 50 kg/cm2 in the second stage, and the emulsion was then dried in a spray dryer to obtain a powder product.

Lactalbumin and skim milk powder shown in Table 3 were powder-powder mixed into this powder product. The powder product thus obtained was placed in a fluidized bed granulator and granulated while spraying purified water into the fluidized bed.

209 pieces of this granule product were sealed in aluminum foil film pouches under a nitrogen seal.

200ml of this sachet of granule product! When I added it to warm water or orange juice and drank it, it tasted delicious and had no fish oil or off-taste.

Furthermore, when the product was stored at room temperature for 6 months and the product was examined after storage, it was found that there was no deterioration odor or strange taste, and there were no quality problems.

(Margins below) Table 3 Example 4 A granule product was obtained in the same manner as in Example 1, except that the enzymatic decomposition product of lactalbumin was changed to skim milk powder.

Example 5 A granule product was obtained in the same manner as in Example 1 except that the enzymatically decomposed product of lactalbumin in Example 1 was changed to the enzymatically decomposed product of egg white.

The products obtained in the above Examples and Comparative Examples were left in a constant temperature bath at 30°C, and the oil content P contained in each product increased over time.
OV was measured by a conventional method and is shown in Table 4.

(The following is a blank space) From the above results, it is clear that the composition of the present invention has extremely excellent oxidation stability.

[Effects of the Invention] The powder composition for preventing blood clots of the present invention has the following characteristics.

(1) Since it has excellent storage stability, it can be easily dissolved and enjoyed as a drink even 4 to 6 months after production.

(2) It has the effect of improving the pathology of arteriosclerotic diseases, thrombotic diseases, and cerebrovascular disorders, and can be used as a therapeutic and preventive agent for these diseases, as it also contains a large amount of protein. It has the effect of increasing physical strength and preventing complications from complications, and can be used for both nutritional maintenance and disease treatment and prevention.

(3) Since it is in the form of powder granules and has extremely good solubility in water, it can be dissolved by simple stirring and can be enjoyed as a beverage. In addition, it can be easily dissolved in concentrated liquid foods, juices, etc., making it easy to use.

(4) Since the emulsification state after dissolution is good, when the solution is left for a long time (for example, used for enteral nutrition), the oil and fat can be used without oxidative deterioration.

Claims (1)

[Scope of Claims] 1 (A) Fats and oils containing 10% by weight or more of eicosapentaenoic acid and docosahexaenoic acid and/or 20 to 70% by weight of fats and oils containing 20% by weight or more of α-linolenic acid, (B) Lecithin 2 20% by weight and (C) a protein and/or a decomposed product thereof 20 to 70% by weight.